IgG1 and IgG3 are the Major Immunoglobulin Subclasses Targeting Epitopes within the NC16A Domain of BP180 in Pemphigoid Gestationis  by Chimanovitch, Iakov et al.
140 LETTERS TO THE EDITOR THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
molecules. Our experiments focused on the injection of the soluble
form of SCF and inhibition of the KIT pathway with monoclonal
antibody K44.2 (Grichnik et al 1998). Because both forms of SCF
stimulate the KIT receptor, we believe the results of our experiments
are applicable for both the soluble and the membrane bound forms
of SCF. K44.2 inhibits the binding of soluble SCF to KIT (Blechman
et al, 1995) but we have no reason to suspect that it does not also
inhibit the binding of membrane bound SCF. Our findings support
the importance of the SCF/KIT interaction to human melanocytes
and do not exclude bound SCF.
While both forms of SCF activate KIT, we suspect that the
duration of activation and potential for receptor degradation is
different for each form. Keratinocytic bound SCF may lock on to
the melanocyte’s KIT receptor resulting in persistent KIT activation
(without KIT receptor internalization and degradation), while
soluble SCF may transiently activate the KIT receptor followed by
internalization and degradation.
The role of KIT on the variety of melanocytic differentiation
states remains for the most part unknown. It is possible that KIT
expression on melanocytes is regulated through at least two
mechanisms, one central (transcriptional) and one peripheral
(feedback through receptor). If the central expression is low the
melanocytic cells may function independently from the KIT
pathway. If central expression is high, then cells become susceptible
to KIT activation or inhibition. Peripheral KIT activation may also
result in apparent KIT downregulation through negative feedback.
Following this logic the KIT 1 TRP-1(–) cells (normal skin,
Grichnik et al, 1996; nevus depigmentous, Dippel et al, 1995)
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To the Editor:
Pemphigoid gestationis (PG) is a subepidermal blistering disease
characterized by the linear depositon of C3 and, to a lesser extent,
IgG at the cutaneous basement membrane zone (BMZ) as detected
by direct immunofluorescence (IF) (Shornick, 1987). Indirect IF
studies demonstrated that circulating autoantibodies of PG sera are
predominantly of the IgG1 subclass (Kelly et al, 1989). The
autoimmune response in PG is directed against two hemidesmo-
somal proteins, BP180 and, less frequently, BP230 (Morrison et al,
1988). The pathogenic relevance of autoantibodies against BP180
in PG and bullous pemphigoid (BP) was established using a passive
transfer animal model (Liu et al, 1993). BP180 is a transmembrane
glycoprotein with a large extracellular C-terminal ectodomain
containing 15 interrupted collageneous domains (Giudice et al,
1992; Hopkinson et al, 1992; Li et al, 1993). Immunoelectron
microscopy studies have shown that the BP180 ectodomain tran-
verses the lamina lucida and projects into the lamina densa (Bedane
et al, 1997; Masunaga et al, 1997). It might interact with one or
more proteins of the epidermal BMZ thus promoting the adhesion
of basal keratinocytes. Recently, it was demonstrated that anti-
BP180 antibodies in BP recognize four major epitopes on its
membrane-proximal NC16A domain (Zillikens et al, 1997a), and
that one of these antigenic sites (designated NC16A2 or MCW-1)
is also recognized by PG sera (Giudice et al, 1993). The purpose
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should be particularly susceptible to KIT inhibition; however, we
have no specific data to support or refute this hypothesis.
There are still quite a number of challenges ahead. How is SCF
normally regulated on human keratinocytes? How is the KIT
receptor regulated on the melanocyte? Is there a functional autocrine
pathway for SCF/KIT in melanocytic disease states? What are the
different differentiation states of melanocytes? Which differentiation
states are dependent or independent of SCF? Can these states be
reversed in normal melanocytes, or in melanoma?
The myriad of different pigmentation states, nevi, and melanoma
types suggests that we have a relatively complex biologic puzzle to
work out. We believe the SCF/KIT pathway will factor into many
of these processes at some capacity. We look forward to the next
millennium and to the answers for many of these questions.
James M. Grichnik
Duke University Medical Center, Division of Dermatology,
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of this study was to characterize the epitopes within BP180 NC16A
targeted by PG autoantibodies and to determine their subclass
distribution.
Sera were obtained from 21 PG patients before treatment was
initiated. All patients showed deposits of C3 and/or IgG at the
BMZ by direct and/or indirect IF and demonstrated autoantibodies
against BP180 NC16A by both ELISA and immunoblot analysis
(Zillikens et al, 1997b). Twelve well-characterized BP sera and 10
normal human sera (NHS) were used as controls. Rabbit serum
R58 was raised against recombinant glutathione S-transferase (GST).
Reactivity of PG sera with different segments of BP180 NC16A
was assayed by immunoblotting using the following recombinant
GST fusion proteins: GST-NC16A1, GST-NC16A2, GST-
NC16A2.5, GST-NC16A3, GST-NC16A1–3, GST-NC16A2–4,
GST-NC16A2–5, and GST-NC16A1–5. Preparation of these pro-
teins, and immunoblotting and immunoadsorption procedures were
performed as described (Giudice et al, 1993; Zillikens et al, 1997a).
The secondary peroxidase-conjugated antibodies were used at the
following dilutions: goat antirabbit polyclonal IgG 1:5000; rabbit
antihuman polyclonal IgG 1:15 000; antihuman IgM 1:5000 (all
DAKO, Glostrup, Denmark); antihuman IgA 1:20 000 (Jackson
Immunoresearch Laboratories, West Grove, PA); sheep antihuman
IgE 1:100; mouse antihuman IgG1 (clone 8c/6–39) 1:1000; anti-
human IgG2 (clone HP6014) 1:500; antihuman IgG3 (clone
HP6050) 1:200; antihuman IgG4 (clone HP6023) 1:4000 (all
Binding Site, Birmingham, UK). Monoclonal antibodies were
demonstrated to be specific by direct hemagglutination and hemag-
glutination inhibition assays (Jefferis et al, 1985), and by immunoblot
analysis using human IgG1, IgG2, IgG3, IgG4 myeloma proteins
(Sigma, St. Louis, MO). Sensitivities of secondary monoclonal
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Figure 1. PG, like BP sera, react with distinct antigenic sites within
BP180 NC16A. Recombinant proteins were fractionated by 15% SDS-
PAGE, transferred to nitrocellulose, and labeled with a PG serum (PG-
KE), a reference control BP serum (BP-KE), and a normal human serum
(NHS). Sera were diluted 1:100 and completely preadsorbed for reactivity
against recombinant GST. Equal amounts of recombinant fusion proteins
NC16A1, NC16A2, NC16A2.5, NC16A3, NC16A1–3, and NC16A1–5
were loaded in lanes 1–6, respectively, as verified by immunoblotting
analysis with rabbit serum R58 raised against recombinant GST. The
migration positions of molecular weight markers of 97, 66, 45, 31, 21,
and 14 kDa are indicated at the left.
Table I. IgG1 and IgG3 are the two major
immunoglobulin subclasses reactive with BP180 NC16A
in PG seraa
IgG1 IgG2 IgG3 IgG4 IgE IgM IgA
17/21b 6/21 14/21 7/21 5/21 2/21 1/21
aImmunoglobulin subclass distribution of autoantibodies in PG sera was analyzed
by immunoblotting using recombinant GST-NC16A1–5 and monoclonal peroxidase-
labeled secondary antibodies.
bNumber of positive sera/number of sera tested.
Figure 2. IgG subclasses and IgE antibodies reveal a similar pattern
of reactivity compared with polyclonal IgG antibodies. Blots
containing equal amounts of fusion proteins NC16A1, NC16A2,
NC16A2.5, NC16A3, NC16A1–3, NC16A1–5 (lanes 1–6, respectively)
were labeled with PG-SP serum (1:100). Bound antibodies were visualized
using peroxidase conjugated antihuman IgG and monoclonal antibodies
against human IgG1, IgG3, and IgE. Molecular weight markers
corresponding to 97, 66, 45, 31, 21, and 14 kDa are indicated at the left.
antibodies used at their working dilutions were shown to be
comparable by immunoblot analysis against equal amounts of
human myeloma proteins.
Like in BP, PG sera revealed major polyclonal IgG reactivity
with NC16A regions 2 (MCW-1) (71%) and 2.5 (MCW-2) (57%)
and showed a reduced level of reactivity with NC16A region 3
(MCW-3) (29%) (Fig 1). In contrast to BP, only 30% of PG sera
reacted with NC16A region 1 (MCW-0) (Zillikens et al, 1997a).
Interestingly, 2 PG sera recognized NC16A region 5 (which we
designate MCW-5) that has not been identified as a target of
autoantibodies so far. Neither PG nor 12 control BP sera reacted
with NC16A region 4 (MCW-4) that is targeted by autoantibodies
in lichen planus pemphigoides (Zillikens et al, 1999).
We identified IgG1 (81%) and IgG3 (67%) as the major subclasses
of PG autoantibodies recognizing BP180 NC16A (Table I). IgG2
and IgG4 reactivity was detected less frequently (33% and 29%,
respectively). In contrast, circulating anti-BMZ antibodies in PG,
as detected by indirect IF, belong almost exclusively to the IgG1
subclass (Kelly et al, 1989). It is, however, important to keep in
mind that the reactivity revealed by indirect IF reflects the binding
properties of autoantibodies to different BMZ proteins, including
BP180 and BP230. The IgG subclass distribution in PG differs
from that in BP, where IgG4 is the major subclass of anti-BP180
NC16A antibodies.1
It is known that some BP sera contain IgE antibodies against
BP230 (Delaporte et al, 1996). In PG, no IgE reactivity has been
reported. We now demonstrate that 24% of PG sera, but none of
10 NHS, show circulating IgE antibodies to BP180 NC16A that
are mainly directed against the MCW-1 epitope (Fig 2). In addition,
we detected IgM and IgA antibodies recognizing BP180 NC16A
in two and one of our 21 PG sera, respectively, but not in NHS.
IgM and IgA anti-BMZ antibodies have been occasionally found
in the skin of PG patients (Wever et al, 1995). In addition, in 13%
of patients with polymorphic eruption of pregnancy, circulating
IgM antibodies to 180 and/or 230 kDa epidermal proteins were
detected (Borradori et al, 1995). No circulating IgM and IgA
antibodies, however, had yet been reported in PG patients. The
pathogenic relevance of IgE, IgM, or IgA isotypes reactive with
BP180 NC16A in PG remains to be elucidated.
We also addressed the question of whether certain subclasses of
PG autoantibodies preferentially react with specific epitopes on
BP180 NC16A. PG sera (n 5 7) revealing the strongest immunoblot
reactivity of the different immunoglobulin subclasses with full-
length BP180 NC16A were assayed against fusion proteins con-
taining different subregions of NC16A. MCW-1 was the epitope
most commonly recognized by autoantibodies of all IgG subclasses
and IgE. In addition, IgG2, IgG3, and IgG4 targeted MCW-2 in
40%–50% of PG sera studied. As we found IgG1 and IgG3 to be
the most common subclasses directed against BP180 NC16A in
PG, the observed preferential reactivity of polyclonal IgG with
MCW-1 and MCW-2 appears to mainly reflect the strong preferen-
tial reactivity of IgG1 and IgG3 with these epitopes (Fig 2).
In conclusion, we demonstrate that PG sera recognize five
distinct epitopes within BP180 NC16A, four of which have been
reported as major antigenic sites targeted by BP autoantibodies
(Zillikens et al, 1997a). In contrast to BP, we found IgG1 and IgG3
to be the major subclasses targeting MCW-1 and MCW-2 within
BP180 NC16A. As IgG3 and IgG1 are the subclasses with the
strongest complement fixing properties, our findings may well
explain complement deposition at the BMZ, which is the most
consistent immunopathological feature in PG and a prerequisite
for the induction of blisters by anti-BP180 antibodies in the mouse
model of PG and BP (Liu et al, 1995).
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